Kenvue Inc

Kenvue Inc (KVUE) Stock Analysis

$18.910

+0.244 (+1.29%)At close

Loading chart…
High
18.945
Open
18.740
VWAP
18.86
Volume
27.69M
Mkt Cap
35.27B
Low
18.715
Amount
522.22M
EV/EBITDA, TTM
11.79

Kenvue Inc. is a consumer health company. The Company's differentiated portfolio of brands includes Aveeno, BAND-AID Brand, Johnson's, Listerine, Neutrogena, Nicorette, Tylenol, and Zyrtec. It operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. Its Self Care product categories include pain care; cough, cold, and allergy; digestive health; smoking cessation; eye care; and other products. Self Care segments include brands such as Tylenol, Motrin, Nicorette, Benadryl, Zyrtec, Zarbee's, Rhinocort, and Calpol. The Skin Health and Beauty segment is focused on face and body care, as well as hair, sun, and other products. The Essential Health segment includes oral care, baby care, women's health, wound care, and other products. Its portfolio includes Self Care, Skin Health and Beauty, and Essential Health products which connect with consumers across North America, Asia Pacific (APAC), Europe, Middle East, and Africa (EMEA), and Latin America (LATAM).

AI analysis of Kenvue Inc (KVUE)

Buy

Kenvue Inc is a good buy right now due to its current price of $17.7 being below the analyst price target of $19, indicating potential upside. Additionally, the forward P/E ratio of 14.73 suggests the stock is reasonably valued compared to its earnings potential. However, the main risk is the RSI at 55.20, which indicates it is approaching overbought territory, suggesting caution may be warranted in the short term.

Analyst Ratings (1)

-0.26% Downside
Sell
0 Buy
0 Hold
1 Sell
Current: 18.91
Low
17.00
Average
18.86
High
23.00

UBS

2026-08-11

Price Target

$19

Neutral

Barclays

2026-07-21

Price Target

$19

Equal Weight

UBS

2026-07-16

Price Target

$20

Neutral

Citi

2026-04-15

Price Target

$19

Neutral

Barclays

2026-04-14

Price Target

$18

Equal Weight

Valuation Metrics

The current forward P/E ratio for Kenvue Inc (KVUE) is 14.73, compared to its 5-year average forward P/E of 17.52.

Forward P/E

Undervalued
5Y Average P/E
17.52
Current P/E
14.73
Overvalued
19.72
Undervalued
15.32

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
12.65
Current EV/EBITDA
11.79
Overvalued
13.79
Undervalued
11.50

Forward P/S

Fair
5Y Average P/S
2.48
Current P/S
2.25
Overvalued
2.81
Undervalued
2.15

Alphio AI Price Scenarios for KVUE

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%KVUE

$25.34

Scenario price

B

Base

Base · 50%KVUE

$22.26

Scenario price

B

Bear

Bear · 25%KVUE

$19.40

Scenario price

Whales holding KVUE

I

Ingalls & Snyder, LLC

+ HoldingKVUE

+9.84%

3M Return

M

Millennium Management LLC

+ HoldingKVUE

+8.78%

3M Return

Y

Yacktman Asset Management LP

+ HoldingKVUE

+7.03%

3M Return

T

Troy Asset Management Ltd

+ HoldingKVUE

+6.32%

3M Return

B

Burgundy Asset Management Ltd.

+ HoldingKVUE

+6.08%

3M Return

Y

Y-Intercept (Hong Kong) Limited

+ HoldingKVUE

+5.48%

3M Return

KVUE FAQ — answered by Alphio AI

Kenvue Inc. is a consumer health company. The Company's differentiated portfolio of brands includes Aveeno, BAND-AID Brand, Johnson's, Listerine, Neutrogena, Nicorette, Tylenol, and Zyrtec. It operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. Its Self Care product categories include pain care; cough, cold, and allergy; digestive health; smoking cessation; eye care; and other products. Self Care segments include brands such as Tylenol, Motrin, Nicorette, Benadryl, Zyrtec, Zarbee's, Rhinocort, and Calpol. The Skin Health and Beauty segment is focused on face and body care, as well as hair, sun, and other products. The Essential Health segment includes oral care, baby care, women's health, wound care, and other products. Its portfolio includes Self Care, Skin Health and Beauty, and Essential Health products which connect with consumers across North America, Asia Pacific (APAC), Europe, Middle East, and Africa (EMEA), and Latin America (LATAM). It operates in the Consumer Non-Cyclicals sector (PERFUMES, COSMETICS & OTHER TOILET PREPARATIONS industry).

Kenvue Inc is a good buy right now due to its current price of $17.7 being below the analyst price target of $19, indicating potential upside. Additionally, the forward P/E ratio of 14.73 suggests the stock is reasonably valued compared to its earnings potential. However, the main risk is the RSI at 55.20, which indicates it is approaching overbought territory, suggesting caution may be warranted in the short term.

1 analysts cover KVUE: 0 rate it Buy, 0 Hold and 1 Sell. The average price target is 18.86.

Community

More ↗

No posts yet

Sign up or log in to join the discussion

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Start trading